AstraZeneca, Buoyed by Cancer Drug Success, Sets Ambitious $80 Billion Target

A decade after fending off a hostile takeover from Pfizer, AstraZeneca PLC (LON: AZN) has cemented its position as a global biopharmaceutical powerhouse, driven by a dominant oncology franchise and a rapidly expanding portfolio of specialty medicines. The company is now embarking on its next chapter of aggressive growth, with CEO Pascal Soriot recently …